SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the company has been granted an expansion of its contract with the U.S.

2023年10月19日（GLOBE NEWSWIRE）-GigaGen Inc.，一家生物技术公司，为免疫缺陷，传染病和检查点抗性癌症推进转化抗体药物，以及Grifols的子公司，今天宣布该公司已获准扩大与美国的合同。

Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop synthetic human antibody treatments for botulinum neurotoxins. The modification, awarded through Army Contracting Command, will expand the value of the agreement to $11.8M.

国防部（DOD）化学，生物，放射和核防御联合计划执行办公室（JPEO-CBRND），为肉毒杆菌神经毒素开发合成人抗体治疗。通过陆军合同指挥部授予的修改将使该协议的价值扩大到1180万美元。

The expanded contract will leverage GigaGen’s novel platform capabilities to rapidly create synthetic human antibodies to protect the warfighter against botulinum neurotoxins (BoNT) A and B and will support advanced development activities including manufacturing and IND-enabling studies to demonstrate improved potency and military utility.

扩展后的合同将利用GigaGen的新型平台功能快速创建合成人体抗体，以保护战士免受肉毒杆菌神经毒素（BoNT）A和B的侵害，并将支持先进的开发活动，包括制造和IND使能研究，以展示更高的效力和军事效用。

“We are very happy to have received this expansion of our initial contract, which affirms DOD’s confidence in our technology and approach and its commitment to support the development of the BoNT hyperimmune product through clinical development,” said Carter Keller, a senior vice president at Grifols and head of GigaGen.

Carter-Keller是一位高级副总裁，他说：“我们非常高兴地收到我们初始合同的扩展，这证实了国防部对我们的技术和方法的信心以及其通过临床开发支持BoNT超免疫产品开发的承诺。”Grifols和GigaGen负责人。

“We are proud of this partnership which will further support the development of our pipeline and platform capabilities and will contribute to the development of key therapeutics against high-priority pathogens.” GigaGen’s next-generation hyperimmune platform offers a novel way to develop recombinant (synthetic) polyclonal antibody therapeutics in the laboratory which are potentially more powerful than what a natural immune response can provide.

“我们为这种伙伴关系感到自豪，这将进一步支持我们的管道和平台能力的发展，并将有助于开发针对高优先级病原体的关键疗法。“GigaGen的下一代超免疫平台提供了一种在实验室开发重组（合成）多克隆抗体疗法的新方法，该疗法可能比天然免疫反应所能提供的更强大。

Using high-throughput, single-.

使用高通量，单一。